Stay updated with breaking news from Alpine Immune Sciences. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- DelveInsight's Systemic Lupus Erythematosus Market Insights report proffers a detailed comprehension of the Systemic Lupus Erythematosus market...
- ALPN-303 uniquely binds BAFF and APRIL with high affinity, differentiating from related inhibitors including wild-type TACI-Fc's - - Ongoing phase 1 study demonstrates highly encouraging preliminary
- ALPN-303 uniquely binds BAFF and APRIL with high affinity, differentiating from related inhibitors including wild-type TACI-Fc’s - - Ongoing phase 1 study demonstrates highly encouraging... | June 1, 2022
Press release content from Business Wire. The AP news staff was not involved in its creation.
FDA Removes Partial Clinical Hold on NEON-2 Clinical Trial of Davoceticept in Combination with Pembrolizumab SEATTLE, Wash., - May 24, 2022 - Alpine Immune... | May 24, 2022